MENU
ENTO
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Entero Therapeutics (ENTO) Ownership - Who owns Entero Therapeutics?
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases... Show more
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
2.9M
P/E Ratio
0.04
Total Cash
366.79K
Projected Growth
N/A
Total Debt
159.67K
Revenue
N/A
Risk (Beta)
0.61
Dividend Yield
N/A
Total Cash/Share
0.08
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
ENTO
Capitalization
2.9M
P/E Ratio
0.04
Risk (Beta)
0.61
Dividend Yield
N/A
Total Cash
367K
Total Cash/Share
0.08
Total Debt
160K
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
8.37M
P/B Ratio
0.35
Cash Flow
N/A
Earnings
13.5
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
474
Current Ratio
5.34
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-18.46M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-22.13
Shares Held By Institutions
63K
Shares Outstanding - Current
4.75M
Total Liabilities
15.8M
Total Volume MTD
N/A
Value
1
Gain YTD
-1.929
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information